FDA Cosmetics Director: ‘Sporadic’ WEN AERs Make Case For Mandatory Reporting
This article was originally published in The Rose Sheet
In a Q&A posting, FDA Office of Cosmetics and Colors Director Linda Katz offered perspective on how the division handles adverse event reports and makes a case for mandatory AE reporting. She also explains how FDA reacted when WEN-related AERs began rolling in.
You may also be interested in...
Linda Katz, director of the FDA’s cosmetics office, says to “stay tuned” for federal legislative developments in 2022, maintaining her position that voluntary adverse-event reporting paints an incomplete picture of consumers’ experience with cosmetic products across the US.
Under current cosmetics regulations FDA does not have the authority to order product recalls, as it does in the dietary supplement space, for example. Voluntary cosmetic recalls have been typically light in recent months, most often citing microbiological issues.
President Trump's budget proposal for fiscal 2018 calls for "targeted reductions to the Food Safety program, including reducing staff levels through attrition." In its justification to congressional appropriators, FDA says it will reduce funding for cosmetics safety work in order to focus on top priorities in the broad foods area.